Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells

Carcinogenesis

Volumn 30, Issue 7, 2009, Pages 1097-1105

  Kawaguchi, Koji ^a,b   Murakami, Hideki ^a   Taniguchi, Tetsuo ^b   Fujii, Makiko ^a   Kawata, Shigehisa ^a   Fukui, Takayuki ^a   Kondo, Yutaka ^a   Osada, Hirotaka ^a   Usami, Noriyasu ^b   Yokoi, Kohei ^b   Ueda, Yuichi ^b   Yatabe, Yasushi ^a   Ito, Masafumi ^c   Horio, Yoshitsugu ^a   Hida, Toyoaki ^a   Sekido, Yoshitaka ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT PLEURA MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MESOTHELIOMA; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 67650132370     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp097     Document Type: Article

References (34)

1. Murayama,T. et al. (2006) Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am. J. Ind. Med., 49, 1-7.
2. Pass,H.I. et al. (2004) Malignant pleural mesothelioma. Curr. Probl. Cancer, 28, 93-174.
3. Peto,J. et al. (1999) The European mesothelioma epidemic. Br. J. Cancer, 79, 666-672.
4. Robinson,B.W. et al. (2005) Advances in malignant mesothelioma. N. Engl. J. Med., 353, 1591-1603.
5. van Meerbeeck,J.P. et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol., 23, 6881-6889.
6. Vogelzang,N.J. et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol., 21, 2636-2644.
7. Kapoor,G.S. et al. (2003) Receptor tyrosine kinase signaling in gliomagenesis: Pathobiology and therapeutic approaches. Cancer Biol. Ther., 2, 330-342.
8. Moasser,M.M. (2007) The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene, 26, 6469-6487.
9. Lynch,T.J. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350, 2129-2139.
10. Paez,J.G. et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
11. Pao,W. et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA, 101, 13306-13311.
12. Garland,L.L. et al. (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J. Clin. Oncol., 25, 2406-2413.
13. Mitsudomi,T. et al. (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci., 98, 1817-1824.
14. Birchmeier,C. et al. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 4, 915-925.
15. Tolnay,E. et al. (1998) Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J. Cancer Res. Clin. Oncol., 124, 291-296.
16. Harvey,P. et al. (1996) Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J. Pathol., 180, 389-394.
17. Jagadeeswaran,R. et al. (2006) Functional analysis of c-Met/ hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res., 66, 352-361.
18. Mukohara,T. et al. (2005) Inhibition of the met receptor in mesothelioma. Clin. Cancer Res., 11, 8122-8130.
19. Kobayashi,S. et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 352 786-792.
20. Engelman,J.A. et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-1043.
21. Usami,N. et al. (2006) Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci., 97, 387-394.
22. Govindan,R. et al. (2005) Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res., 11, 2300-2304.
23. Destro,A. et al. (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer, 51, 207-215.
24. Altomare,D.A. et al. (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene, 24, 6080-6089.
25. Beau-Faller,M. et al. (2008) MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J. Thorac. Oncol., 3, 331-339.
26. Di Renzo,M.F. et al. (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res., 1, 147-154.
27. Taniguchi,T. et al. (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci., 98, 438-446.
28. Stommel,J.M. et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287-290.
29. Versnel,M.A. et al. (1991) Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene, 6, 2005-2011.
30. Ramael,M. et al. (1992) Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol., 167, 1-4.
31. Langerak,A.W. et al. (1996) Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J. Pathol., 178, 151-160.
32. Mathy,A. et al. (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer, 50, 83-86.
33. Porta,C. et al. (2007) Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother. Pharmacol., 59, 149-150.
34. Suzuki,Y. et al. (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol. Med. Rep., 2, 181-188.